CRYSTALLINE FORM OF 5(S)-(2-HYDROXYETHOXY)-20(S)-CAMPTOTHECIN
申请人:Akella Venkateswarlu
公开号:US20080076790A1
公开(公告)日:2008-03-27
A crystalline form of 5(S)-(2′-hydroxyethoxy)-20(S)-camptothecin diastereoisomer of 5(RS)-(2′-hydroxyethoxy)-20(S)-camptothecin is described that is characterized by having an X-ray powder diffraction pattern comprising one or more peak intensities expressed in degrees 2θ that are selected from the group consisting of 7.2±0.1, 9.4±0.1, 11.02±0.1, 12.00±0.1, 14.54±0.1, 15.2±0.1, 18.92±0.1, 21.86±0.1, 22.74±0.1 and 26.42±0.1. Methods of making and using the compound are also described.
5(S)-(2'-HYDROXYETHOXY)-20(S)-CAMPTOTHECIN AND ITS PREPARATION AND USE FOR THE TREATMENT OF CANCER
申请人:Akella Venkateswarlu
公开号:US20080076791A1
公开(公告)日:2008-03-27
A 5(S)-(2′-hydroxyethoxy)-20(S)-camptothecin diasterisomer is described which is a better inhibitor of topoisomerase I than either the diastereoisomeric mixture 5(RS)-(2′-hydroxyethoxy)-20(S)-camptothecin, or the 5(R)-(2′-hydroxyethoxy)-20(S)-camptothecin diastereoisomer. Pharmaceutical compositions of the 5(S)-(2′-hydroxyethoxy)-20(S)-camptothecin diastereoisomer are also described as are methods of using the compound for the inhibition of topoisomerase I and for the treatment of cancer.
PHARMACEUTICAL COMPOSITIONS OF [5(S)-(2'-HYDROXYETHOXY)-20(S)-CAMPTOTHECIN
申请人:Nekkanti Vijay Kumar
公开号:US20110177161A1
公开(公告)日:2011-07-21
There is provided a powder composition for use in a pharmaceutical product, the composition including a) 5(S)-(2′-hydroxyethoxy)-20(S)-CPT; at least one cyclodextrin; wherein 5(S)-(2′-hydroxyethoxy)-20(S)-CPT includes less than 5% of 5(R)-(2′-hydroxyethoxy)-20(S)-CPT. Preferably, in the powder composition, 5(S)-(2′-hydroxyethoxy)-20(S)-CPT is substantially free from said 5(R)-(2′-hydroxyethoxy)-20(S)-CPT.